Report cover image

Particle Therapy Market (Therapy: Proton Therapy and Heavy Ion Therapy; Service: Cyclotrons, Synchrotrons, and Synchrocyclotrons) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Publisher Transparency Market Research Pvt. Ltd.
Published May 05, 2022
Length 230 Pages
SKU # TNPR17326535

Description

Particle Therapy Market (Therapy: Proton Therapy and Heavy Ion Therapy; Service: Cyclotrons, Synchrotrons, and Synchrocyclotrons) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Companies Mentioned

Varian Medical Systems, Inc.
Sumitomo Heavy Industries, Ltd.
Provision Healthcare
Protom International, Inc.
Optivus Proton Therapy, Inc.
Mevion Medical Systems, Inc.
IBA Worldwide
Hitachi, Ltd.
Danfysik A/S
Advanced Oncotherapy plc

Countries

North America
Europe
Asia Pacific
Rest of the World

Forecast Year (first) - 2022

Forecast Year (last) - 2031

Forecast Year ( first)  Value - 560.3

Forecast Year (last) Value - 1267.16

CAGR % - 0.086

Currency - US$ Mn

Table of Contents

230 Pages
1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Particle Therapy Market
4. Market Overview
    4.1. Introduction
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Particle Therapy Market Analysis and Forecast, 2017–2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Technological Advancements
    5.2. Reimbursement Scenario
    5.3. Particle Therapy Facilities In Clinical Operation, 2021
    5.4. Average Prices, by Region, 2021
    5.5. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
6. Global Particle Therapy Market Analysis and Forecast, By Therapy
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Therapy, 2017–2031
        6.3.1. Proton Therapy
        6.3.2. Heavy Ion Therapy (carbon therapy, He, pion)
    6.4. Market Attractiveness Analysis, By Therapy
7. Global Particle Therapy Market Analysis and Forecast, By Application
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Application, 2017–2031
        7.3.1. Pediatric Cancer
        7.3.2. Lung Cancer
        7.3.3. Bladder Cancer
        7.3.4. Brain & Spinal Cord Tumors (BSCT)
        7.3.5. Breast Cancer
        7.3.6. Gastrointestinal (GI) Cancers
        7.3.7. Hepatocellular Carcinoma (HCC)
        7.3.8. Head & Neck Cancers (HNC)
        7.3.9. Others
    7.4. Market Attractiveness Analysis, By Application
8. Global Particle Therapy Market Analysis and Forecast, By Service
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Service, 2017–2031
        8.3.1. Cyclotrons
        8.3.2. Synchrotrons
        8.3.3. Synchrocyclotrons
    8.4. Market Attractiveness Analysis, By Service
9. Global Particle Therapy Market Analysis and Forecast, By End-user
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by End-user, 2017–2031
        9.3.1. Hospitals
        9.3.2. Academic & Research Centers
    9.4. Market Attractiveness Analysis, By End-user
10. Global Particle Therapy Market Analysis and Forecast, By Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Rest of the World
    10.3. Market Attractiveness Analysis, By Region
11. North America Particle Therapy Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Therapy, 2017–2031
        11.2.1. Proton Therapy
        11.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
    11.3. Market Value Forecast, by Application, 2017–2031
        11.3.1. Pediatric Cancer
        11.3.2. Lung Cancer
        11.3.3. Bladder Cancer
        11.3.4. Brain & Spinal Cord Tumors (BSCT)
        11.3.5. Breast Cancer
        11.3.6. Gastrointestinal (GI) Cancers
        11.3.7. Hepatocellular Carcinoma (HCC)
        11.3.8. Head & Neck Cancers (HNC)
        11.3.9. Others
    11.4. Market Value Forecast, by Service, 2017–2031
        11.4.1. Cyclotrons
        11.4.2. Synchrotrons
        11.4.3. Synchrocyclotrons
    11.5. Market Value Forecast, by End-user, 2017–2031
        11.5.1. Hospitals
        11.5.2. Academic & Research Centers
    11.6. Market Value Forecast, by Country, 2017–2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Therapy
        11.7.2. By Application
        11.7.3. By Service
        11.7.4. By End-user
        11.7.5. By Country
12. Europe Particle Therapy Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Therapy, 2017–2031
        12.2.1. Proton Therapy
        12.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
    12.3. Market Value Forecast, by Application, 2017–2031
        12.3.1. Pediatric Cancer
        12.3.2. Lung Cancer
        12.3.3. Bladder Cancer
        12.3.4. Brain & Spinal Cord Tumors (BSCT)
        12.3.5. Breast Cancer
        12.3.6. Gastrointestinal (GI) Cancers
        12.3.7. Hepatocellular Carcinoma (HCC)
        12.3.8. Head & Neck Cancers (HNC)
        12.3.9. Others
    12.4. Market Value Forecast, by Service, 2017–2031
        12.4.1. Cyclotrons
        12.4.2. Synchrotrons
        12.4.3. Synchrocyclotrons
    12.5. Market Value Forecast, by End-user, 2017–2031
        12.5.1. Hospitals
        12.5.2. Academic & Research Centers
    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Spain
        12.6.5. Italy
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Therapy
        12.7.2. By Application
        12.7.3. By Service
        12.7.4. By End-user
        12.7.5. By Country/Sub-region
13. Asia Pacific Particle Therapy Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Therapy, 2017–2031
        13.2.1. Proton Therapy
        13.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
    13.3. Market Value Forecast, by Application, 2017–2031
        13.3.1. Pediatric Cancer
        13.3.2. Lung Cancer
        13.3.3. Bladder Cancer
        13.3.4. Brain & Spinal Cord Tumors (BSCT)
        13.3.5. Breast Cancer
        13.3.6. Gastrointestinal (GI) Cancers
        13.3.7. Hepatocellular Carcinoma (HCC)
        13.3.8. Head & Neck Cancers (HNC)
        13.3.9. Others
    13.4. Market Value Forecast, by Service, 2017–2031
        13.4.1. Cyclotrons
        13.4.2. Synchrotrons
        13.4.3. Synchrocyclotrons
    13.5. Market Value Forecast, by End-user, 2017–2031
        13.5.1. Hospitals
        13.5.2. Academic & Research Centers
    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Therapy
        13.7.2. By Application
        13.7.3. By Service
        13.7.4. By End-user
        13.7.5. By Country/Sub-region
14. Rest of the World Particle Therapy Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Therapy, 2017–2031
        14.2.1. Proton Therapy
        14.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
    14.3. Market Value Forecast, by Application, 2017–2031
        14.3.1. Pediatric Cancer
        14.3.2. Lung Cancer
        14.3.3. Bladder Cancer
        14.3.4. Brain & Spinal Cord Tumors (BSCT)
        14.3.5. Breast Cancer
        14.3.6. Gastrointestinal (GI) Cancers
        14.3.7. Hepatocellular Carcinoma (HCC)
        14.3.8. Head & Neck Cancers (HNC)
        14.3.9. Others
    14.4. Market Value Forecast, by Service, 2017–2031
        14.4.1. Cyclotrons
        14.4.2. Synchrotrons
        14.4.3. Synchrocyclotrons
    14.5. Market Value Forecast, by End-user, 2017–2031
        14.5.1. Hospitals
        14.5.2. Academic & Research Centers
    14.6. Market Attractiveness Analysis
        14.6.1. By Therapy
        14.6.2. By Application
        14.6.3. By Service
        14.6.4. By End-user
15. Competition Landscape
    15.1. Market Player - Competition Matrix (by tier and size of companies)
    15.2. Market Share Analysis, by Company, 2020
    15.3. Company Profiles
        15.3.1. Advanced Oncotherapy plc
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Strategic Overview
        15.3.2. Danfysik A/S
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Strategic Overview
        15.3.3. Hitachi, Ltd.
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Strategic Overview
        15.3.4. IBA Worldwide
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Strategic Overview
        15.3.5. Mevion Medical Systems, Inc.
            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Strategic Overview
        15.3.6. Optivus Proton Therapy, Inc.
            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Strategic Overview
        15.3.7. Protom International, Inc.
            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Strategic Overview
        15.3.8. Provision Healthcare
            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Strategic Overview
        15.3.9. Sumitomo Heavy Industries, Ltd.
            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Strategic Overview
        15.3.10. Varian Medical Systems, Inc.
            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.10.2. Product Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Strategic Overview

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us